A comprehensive model for assessing and classifying patients with thrombotic microangiopathy: the TMA-INSIGHT score.
Atypical hemolytic uremic syndrome
Complement mediated TMA
Shiga toxin-mediated hemolytic uremic syndrome
Thrombotic Thrombocytopenic Purpura
Thrombotic microangiopathy
Journal
Thrombosis journal
ISSN: 1477-9560
Titre abrégé: Thromb J
Pays: England
ID NLM: 101170542
Informations de publication
Date de publication:
22 Nov 2023
22 Nov 2023
Historique:
received:
15
08
2023
accepted:
13
11
2023
medline:
23
11
2023
pubmed:
23
11
2023
entrez:
23
11
2023
Statut:
epublish
Résumé
Thrombotic Microangiopathy (TMA) is a syndrome characterized by the presence of anemia, thrombocytopenia and organ damage and has multiple etiologies. The primary aim is to develop an algorithm to classify TMA (TMA-INSIGHT score). This was a single-center retrospective cohort study including hospitalized patients with TMA at a single center. We included all consecutive patients diagnosed with TMA between 2012 and 2021. TMA was defined based on the presence of anemia (hemoglobin level < 10 g/dL) and thrombocytopenia (platelet count < 150,000/µL), signs of hemolysis, and organ damage. We classified patients in eight categories: infections; Malignant Hypertension; Transplant; Malignancy; Pregnancy; Thrombotic Thrombocytopenic Purpura (TTP); Shiga toxin-mediated hemolytic uremic syndrome (STEC-SHU) and Complement Mediated TMA (aHUS). We fitted a model to classify patients using clinical characteristics, biochemical exams, and mean arterial pressure at presentation. We retrospectively retrieved TMA phenotypes using automatic strategies in electronic health records in almost 10 years (n = 2407). Secondary TMA was found in 97.5% of the patients. Primary TMA was found in 2.47% of the patients (TTP and aHUS). The best model was LightGBM with accuracy of 0.979, and multiclass ROC-AUC of 0.966. The predictions had higher accuracy in most TMA classes, although the confidence was lower in aHUS and STEC-HUS cases. Secondary conditions were the most common etiologies of TMA. We retrieved comorbidities, associated conditions, and mean arterial pressure to fit a model to predict TMA and define TMA phenotypic characteristics. This is the first multiclass model to predict TMA including primary and secondary conditions.
Sections du résumé
BACKGROUND
BACKGROUND
Thrombotic Microangiopathy (TMA) is a syndrome characterized by the presence of anemia, thrombocytopenia and organ damage and has multiple etiologies. The primary aim is to develop an algorithm to classify TMA (TMA-INSIGHT score).
METHODS
METHODS
This was a single-center retrospective cohort study including hospitalized patients with TMA at a single center. We included all consecutive patients diagnosed with TMA between 2012 and 2021. TMA was defined based on the presence of anemia (hemoglobin level < 10 g/dL) and thrombocytopenia (platelet count < 150,000/µL), signs of hemolysis, and organ damage. We classified patients in eight categories: infections; Malignant Hypertension; Transplant; Malignancy; Pregnancy; Thrombotic Thrombocytopenic Purpura (TTP); Shiga toxin-mediated hemolytic uremic syndrome (STEC-SHU) and Complement Mediated TMA (aHUS). We fitted a model to classify patients using clinical characteristics, biochemical exams, and mean arterial pressure at presentation.
RESULTS
RESULTS
We retrospectively retrieved TMA phenotypes using automatic strategies in electronic health records in almost 10 years (n = 2407). Secondary TMA was found in 97.5% of the patients. Primary TMA was found in 2.47% of the patients (TTP and aHUS). The best model was LightGBM with accuracy of 0.979, and multiclass ROC-AUC of 0.966. The predictions had higher accuracy in most TMA classes, although the confidence was lower in aHUS and STEC-HUS cases.
CONCLUSION
CONCLUSIONS
Secondary conditions were the most common etiologies of TMA. We retrieved comorbidities, associated conditions, and mean arterial pressure to fit a model to predict TMA and define TMA phenotypic characteristics. This is the first multiclass model to predict TMA including primary and secondary conditions.
Identifiants
pubmed: 37993892
doi: 10.1186/s12959-023-00564-6
pii: 10.1186/s12959-023-00564-6
pmc: PMC10664252
doi:
Types de publication
Journal Article
Langues
eng
Pagination
119Informations de copyright
© 2023. The Author(s).
Références
Am J Kidney Dis. 2014 May;63(5):713-35
pubmed: 24647050
Clin Chem Lab Med. 2015 Oct;53(11):1679-88
pubmed: 25803082
Thromb Res. 2020 Sep;193:154-159
pubmed: 32622194
Lancet Haematol. 2017 Apr;4(4):e157-e164
pubmed: 28259520
Clin Kidney J. 2022 Apr 11;15(8):1601-1611
pubmed: 35892013
Front Immunol. 2019 Feb 27;10:337
pubmed: 30891033
Clin J Am Soc Nephrol. 2019 Apr 5;14(4):557-566
pubmed: 30862697
BMC Nephrol. 2022 Jan 20;23(1):39
pubmed: 35057750
Biomedicines. 2023 Mar 13;11(3):
pubmed: 36979866
Lancet. 2022 Nov 12;400(10364):1722-1740
pubmed: 36272423
Kidney Int. 2017 Mar;91(3):539-551
pubmed: 27989322
Lancet. 2017 Aug 12;390(10095):681-696
pubmed: 28242109
Front Med (Lausanne). 2021 Feb 26;8:566678
pubmed: 33718396
Br J Haematol. 2014 Mar;164(6):759-66
pubmed: 24387053
Chest. 2017 Aug;152(2):424-434
pubmed: 28442312
PLoS One. 2010 Apr 23;5(4):e10208
pubmed: 20436664
CMAJ. 2017 Jan 30;189(4):E153-E159
pubmed: 27754896
Front Med (Lausanne). 2021 Oct 05;8:747612
pubmed: 34676229
Int J Lab Hematol. 2022 Sep;44 Suppl 1:101-113
pubmed: 36074708
Clin Kidney J. 2019 Jun 18;13(2):208-216
pubmed: 32296526